Interaction Checker

Interacciones de Icosapento de etilo

Icosapento de etilo (Vascepa), ácido graso omega-3, tiene 33 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 33; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (33)

  • Aceite de pescado (omega-3)Plantas medicinales y suplementosModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Ácido acetilsalicílicoAINEModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Ácido acetilsalicílico y dipiridamolantiagregante plaquetarioModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • ApixabánanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • ArgatrobánanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • AtorvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • BivalirudinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico y cafeínabarbitúricoModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Cangrelorantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Cilostazolantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Clopidogrelantiagregante plaquetarioModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • DabigatránanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Dipiridamolantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • EdoxabánanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Eptifibatidaantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Ezetimiba y simvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • FluvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • HeparinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • LovastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Orfenadrina, ácido acetilsalicílico y cafeínarelajante muscularModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • PitavastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Prasugrelantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • PravastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • RivaroxabánanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • RosuvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • SimvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (etiqueta de Icosapento de etilo, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • Tirofibánantiagregante plaquetarioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (etiqueta de Icosapento de etilo, Interacciones medicamentosas)

  • WarfarinaanticoagulanteModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

Compruebe Icosapento de etilo frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.